Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday it will repurchase 100 billion won (US$73 million) worth of its own shares as part of its corporate value-up program.

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

Celltrion will establish a fully owned subsidiary aimed at contract development and manufacturing (CDMO) by the end of this year, the pharmaceutical firm said on Friday.

Celltrion has finally merged with Celltrion Healthcare, three years after its original plan was announced. Celltrion announced that its board had approved the merger on Thursday. Each share of ...

INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab ...

Celltrion has been increasing its return to shareholders, as evidenced by cash dividends increasing to KRW 153.8 billion in 2024 from KRW 51.7 billion in 2022.

INCHEON, South Korea, May 23, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

Janssen’s suit against Celltrion in the District of Massachusetts (C.A. No. 1:15-cv-10698) is one of the few currently pending litigations related to biosimilars and the BPCIA.